Mulherin Stephanie A, O'Brien Thomas R, Ioannidis John P, Goedert James J, Buchbinder Susan P, Coutinho Roel A, Jamieson Beth D, Meyer Laurence, Michael Nelson L, Pantaleo Giuseppe, Rizzardi G Paolo, Schuitemaker Hanneke, Sheppard Haynes W, Theodorou Ioannis D, Vlahov David, Rosenberg Philip S
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH/DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA.
AIDS. 2003 Feb 14;17(3):377-87. doi: 10.1097/01.aids.0000050783.28043.3e.
To examine temporal variation in the effects of CCR5-Delta32 and CCR2-64I chemokine receptor gene polymorphisms on HIV-1 disease progression.
Pooled analysis of individual patient data from 10 cohorts of HIV-1 seroconverters from the United States, Europe, and Australia.
We studied HIV-1 seroconverters of European (n = 1635) or African (n = 215) ancestry who had been genotyped for CCR5-Delta32 and CCR2-64I. We used Cox proportional hazards models with time-varying coefficients to determine whether the genetic protection against AIDS (1987 case definition) and death varied with time since seroconversion.
Protection against AIDS conferred by CCR5-Delta32 held constant at a 31% (RH 0.69, 95% CI 0.54, 0.88) reduction in risk over the course of HIV-1 infection, whereas protection against death held constant at a 39% reduction in risk (RH 0.61, 95% CI 0.45, 0.88). When the period from AIDS to death was isolated, the survival benefit of CCR5-Delta32 diminished 2 years after AIDS. Protection against AIDS conferred by CCR2-64I was greatest early in the disease course. Compared with individuals without CCR5-Delta32 or CCR2-64I, individuals with one or two copies of CCR2-64I had a 58% lower risk of AIDS during the first 4 years after seroconversion (RH 0.42, 95% CI 0.23, 0.76), a 19% lower risk during the subsequent 4 years (RH 0.81, 95% CI 0.59, 1.12), and no significant protection thereafter.
The protection against AIDS provided by CCR5-Delta32 is continuous during the course of infection. In contrast, the protection provided by CCR2-64I is greatest early in the course of infection.
研究CCR5 - Δ32和CCR2 - 64I趋化因子受体基因多态性对HIV - 1疾病进展影响的时间变化。
对来自美国、欧洲和澳大利亚的10个HIV - 1血清转化者队列的个体患者数据进行汇总分析。
我们研究了欧洲血统(n = 1635)或非洲血统(n = 215)的HIV - 1血清转化者,这些人已对CCR5 - Δ32和CCR2 - 64I进行了基因分型。我们使用具有时变系数的Cox比例风险模型来确定针对艾滋病(1987年病例定义)和死亡的基因保护是否随血清转化后的时间而变化。
在HIV - 1感染过程中,CCR5 - Δ32对艾滋病的保护作用保持恒定,风险降低31%(相对风险0.69,95%置信区间0.54,0.88),而对死亡的保护作用保持恒定,风险降低39%(相对风险0.61,95%置信区间0.45,0.88)。当将从艾滋病到死亡的时间段单独分离出来时,CCR5 - Δ32的生存益处在艾滋病发生2年后减弱。CCR2 - 64I对艾滋病的保护作用在疾病进程早期最大。与没有CCR5 - Δ32或CCR2 - 64I的个体相比,具有一份或两份CCR2 - 64I拷贝的个体在血清转化后的前4年患艾滋病的风险降低58%(相对风险0.42,95%置信区间0.23,0.76),在随后的4年中风险降低19%(相对风险0.81,9%置信区间0.59,1.12),此后无显著保护作用。
CCR5 - Δ32在感染过程中对艾滋病的保护作用是持续的。相比之下,CCR2 - 64I在感染过程早期提供的保护作用最大。